Methods of treating non-muscle invasive bladder cancer

Intravesical administration of cretostimogene grenadenorepvec addresses the treatment gap for IR-NMIBC by reducing recurrence and progression through a targeted oncolytic virus approach, providing effective and prolonged survival without additional immune modulators.

WO2026096653A1PCT designated stage Publication Date: 2026-05-07CG ONCOLOGY INC
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
CG ONCOLOGY INC
Filing Date
2025-10-29
Publication Date
2026-05-07

Smart Images

  • Figure US2025053143_07052026_PF_FP_ABST
    Figure US2025053143_07052026_PF_FP_ABST
Patent Text Reader

Abstract

The present invention provides methods for treating an individual having intermediate-risk non-muscle invasive bladder cancer comprising intravesically administering to the individual an oncolytic virus. Also provided are pharmaceutical compositions and kits for treating intermediate-risk non-muscle invasive bladder cancer.
Need to check novelty before this filing date? Find Prior Art